New Synthetic Antifungal Agents – Variations to kanamycin A, kanamycin B, and tobramycin

Technical Summary

•  Dr. Tom Chang and Dr. Jon Takemoto of Utah State University’s Chemistry/Biochemistry and Biology departments have developed a novel group of fungicides through the derivation of aminoglycoside antibiotics kanamycins A and B and tobramycin.

•  Because many aminoglycosides have become obsolete, researchers have placed considerable effort to produce novel and effective antifungal compounds.  These compounds (like K20, another Utah State University development) are distinguishable from their parent molecules by the presence of functional groups terminating in either an alkyl or phenyl group in the 6 position of ring III.  A preferred embodiment of these compounds is the treatment of fungal infections in a host wherein bacterial elimination is undesirable.

Commercial Applications

•  Potential commercial partners:

•  Pharmaceutical companies

•  Medical and chemical supply companies

•  Agrichemical companies

•  Crop protection suppliers

•  May be used to treat fungal diseases of humans as well as agricultural crops

•  Shows considerable activity against Fusarium species (crop diseases) and Candida and Cryptococcus species (animal mycoses).

•  May be administered through spraying, direct injection, topical application, oral administration, or by inclusion to the water supply.

Competitive Advantages

•  Derived from available parent molecules, kanamycin A and B

•  Novel mechanism of action

•  Low toxicity and environmentally friendly

Related Technologies

•  New Synthetic Antifungal Agents – K20 and Related Compounds (P10039)

•  New Synthetic Antifungal Agents – K20 and Azole-based Fungicides (P13013)

 

Patent Information:
Category(s):
Agriculture and Food Science
For Information, Contact:
Christian Iverson
Utah State University
435-797-9620
christian.iverson@usu.edu
Inventors:
Cheng-Wei Chang Jon Takemoto
Keywords: